Sanofi’s Aubagio recommended for use on UK’s NHSThe UK’s National Institute for Clinical and Health Excellence has issued final draft guidance recommending the NHS to Share XSanofi’s Aubagio recommended for use on UK’s NHShttps://pharmaphorum.com/news/sanofis-aubagio-recommended-for-use-on-uks-nhs/
Phase 3 goal met by Novartis’ multiple myeloma drugNovartis’ investigational compound, LBH589, for multiple myeloma has met its primary endpoint in phase 3 clinical trials. LBH589 Share XPhase 3 goal met by Novartis’ multiple myeloma drughttps://pharmaphorum.com/news/phase-3-goal-met-by-novartis-multiple-myeloma-drug/
Lilly’s depression drug fails to meet goal in phase 3Eli Lilly and Company’s edivoxetine did not meet its primary endpoint in phase 3 clinical trials as an Share XLilly’s depression drug fails to meet goal in phase 3https://pharmaphorum.com/news/lilly-s-depression-drug-fails-to-meet-goal-in-phase-3/
Digital health perspectives: Matt McNallyMatt McNally, President of Publicis Health Media offers his insight into digital engagement in our latest ‘Digital health Share XDigital health perspectives: Matt McNallyhttps://pharmaphorum.com/views-and-analysis/digital-health-perspectives-matt-mcnally/
Roche, Molecular Partners in cancer deal worth over $1 billionRoche and Molecular Partners have entered into a research and licensing alliance to discover, develop and commercialize new Share XRoche, Molecular Partners in cancer deal worth over $1 billionhttps://pharmaphorum.com/news/roche-molecular-partners-in-cancer-deal-worth-over-1-billion/
Sanofi reports positive phase 3 insulin dataFull results from Sanofi’s phase three clinical trials of its investigational new insulin U300 have been announced. The Share XSanofi reports positive phase 3 insulin datahttps://pharmaphorum.com/news/sanofi-reports-positive-phase-3-insulin-data/
Defects and the development risk defence – an Australian perspectiveMabel Tsui provides us with an Australian perspective on the development risk defence against a pharmaceutical product liability Share XDefects and the development risk defence – an Australian perspectivehttps://pharmaphorum.com/views-and-analysis/defects-and-the-development-risk-defence-an-australian-perspective/
Celgene, OncoMed sign $155m cancer dealOncoMed Pharmaceuticals and Celgene Corporation have signed an agreement to jointly develop and commercialize up to six anti-cancer Share XCelgene, OncoMed sign $155m cancer dealhttps://pharmaphorum.com/news/celgene-oncomed-sign-155m-cancer-deal/
Positive phase 3 for Novo Nordisk combination diabetes drugNovo Nordisk has announced that a phase 3 clinical trial of its diabetes drug, Ryzodeg, showed improved control Share XPositive phase 3 for Novo Nordisk combination diabetes drughttps://pharmaphorum.com/news/positive-phase-3-for-novo-nordisk-combination-diabetes-drug/
